The new gold standard in clinical research: direct-to-patient.
PicnicResearch uses a patient-mediated approach to maximize the long-term value of your trial and generate decision-grade evidence. By combining our scientific expertise, patient-connected study design, and AI-enhanced infrastructure, we help you answer your research questions and maintain a connection with patients to accelerate your programs.
Published with the biggest names in life sciences
top life sciences companies work with us
of studies enroll ahead of forecast
within one day
more cost effective than traditional models
Traditional research approaches weren't built for the questions sponsors actually need to answer.
Drug development demands more from evidence generation than ever before. Traditional options force tradeoffs that compromise the evidence quality regulators, payers, and development teams require.
Rigorous, but slow and rigid
Site networks offer control but are slow to stand up, geographically constrained, expensive to amend, and structurally biased toward academic centers — missing much of the treated population.
Often required, but rarely planned for
When trials end, structured follow-up ends with them. PMCs, PMRs, and REMS programs obligate long-term evidence generation — but the infrastructure to support it is rarely in place.
Abundant, but too shallow
Claims databases and EHR aggregators are fast and low-cost, but meet research-grade completeness requirements only ~30% of the time — a gap that widens further in rare disease.
A direct-to-patient evidence platform built around your scientific question.
PicnicResearch doesn't start with a generic dataset. We start with the question. Every study is designed around defined scientific and regulatory objectives — then built with the infrastructure to answer them.
Direct to patient, site agnostic
Patients enroll remotely. We retrieve complete medical records across all treating providers using patient right of access, no site network required.
Reusable, not one-off
The evidence asset evolves as your program does. Return to the same cohort as new questions emerge, scale rigor up or down, and build a strategic foundation rather than a series of disconnected studies.
Research- and regulatory-grade
IRB oversight, fully traceable data capture, and scientifically designed protocols produce evidence built for regulatory submissions and HTA dossiers, not just directional signals.
Deep, longitudinal, multi-modal
5-7+ years of curated retrospective records, ongoing prospective follow-up, PROs, and primary data collection integrated into a unified, living data asset.
Built for today's clinical research challenges.
Each meets a distinct need across the drug development lifecycle, from recruiting patients to generating decision-grade evidence, all built on the same direct-to-patient platform.
Decision-grade evidence from participants enrolled through multi-channel recruitment strategies including speciality pharmacies and patient support programs — reaching the full treatment population, not just the patients a site network can find.
Built to support clinical research across the asset lifecycle.
Our platform serves five functional areas — each with distinct questions, distinct timelines, and a common need for a better approach than the traditional model.
HEOR
Disease burden & QoL, treatment patterns, payer evidence, comparative effectiveness
Medical affairs
Patient journey, unmet need, real-world safety, treatment burden
Market access
HTA dossiers, payer submissions, patient experience, QoL outcomes
Commercial
Demonstrate product value, support label expansions, optimize target strategies
Clinical development
Natural history, external controls, PMC/PMR obligations, long-term safety
